Industry Summary
The efficacy of immune cell therapy “living drugs” is outstanding, and the global research and development enthusiasm continues
Immune cell therapy is a “living drug” in tumor immunotherapy, with prominent efficacy advantages. The first generation of CAR overcomes the MHC restriction of TCR, and each generation of CAR aims to enhance cell proliferation and lethality. Development history: CAR-T has come from behind, with remarkable curative effects in hematological tumors, and has been repeatedly approved by the FDA. The global research and development of immune cell therapy continues to heat up, and China ranks second in the world.
Research and development status and breakthrough ideas of immune cell therapy
CAR-T occupies “half of the country”, NK continues to increase rapidly, and the growth rate of TCR-T and TIL therapy slows down. The autologous preparation and high price of CAR-T approved products hinder the accessibility of patients, and the indications are clustered in hematological tumors. Breakthrough ideas: (1) off-the-shelf general-purpose products have more commercial prospects, (2) conquer solid tumors that account for 90% of the market, and find differentiated targets.
Talking about the development prospect of technology path perspective
CAR-NK has both safety and efficacy advantages, and the commercialization of iPSC-derived NK has broad prospects. Different technical paths have their own magical powers, CAR-NK or the final path. CAR-T: Good efficacy in hematological tumors; but little prospect for commercialization. UCAR-T: Significantly lower cost; but discounted efficacy. TCR-T: broad intracellular antigen recognition; but not universal. CAR-NK: Best safety profile, extremely low cost; repeated infusions overcome durability. TIL: broad-spectrum anti-solid tumor; but the sampling preparation is cumbersome.
To view the full report click here
Note: Unless it is marked as original, it is all submitted by netizens or institutions for sharing. If you have any needs for publicity, please contact [email protected].
This article is reprinted from: https://www.dx2025.com/archives/26448.html
This site is for inclusion only, and the copyright belongs to the original author.